Patents by Inventor Dirk Gottschling

Dirk Gottschling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12156874
    Abstract: The present invention relates to compounds of formula (I) wherein A, X, R1, R2, R3, R4 and R5 are as defined herein, and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, such as hypertension, preeclampsia, restenosis, a cardiac or respiratory condition, renal disease, liver disease, muscular dystrophy, fibrotic disorders, pain, ischemia or ischemic reperfusion injury, and cancer.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: December 3, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Thierry Bouyssou, Niklas Heine
  • Patent number: 11370771
    Abstract: The present invention relates to polycyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R4, R7 to R10, Y and A are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: June 28, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Kay Berry, Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Matthew Russell Netherton
  • Publication number: 20210163449
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 8, 2020
    Publication date: June 3, 2021
    Applicants: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Patent number: 10889568
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: January 12, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Patent number: 10800757
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: October 13, 2020
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20190169167
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Publication number: 20190169168
    Abstract: The invention relates to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R7, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 6, 2019
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu
  • Patent number: 10307402
    Abstract: The present invention relates to compounds of general formula I, wherein the group R1, X and Y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the AMP-activated protein kinase (AMPK) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 4, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Joerg P. Hehn, Christoph Hoenke, Elke Langkopf
  • Patent number: 10093660
    Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    Type: Grant
    Filed: November 28, 2014
    Date of Patent: October 9, 2018
    Assignee: EVOTEC INTERNATONAL GMBH
    Inventors: Joerg Kley, Andreas Blum, Dirk Gottschling, Joerg P. Hehn, Dieter Wiedenmayer
  • Patent number: 9708274
    Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: July 18, 2017
    Assignee: EVOTEC INTERNATIONAL GMBH
    Inventors: Andreas Blum, Dirk Gottschling, Armin Heckel, Joerg P. Hehn, Bernhard Schmid, Dieter Wiedenmayer
  • Publication number: 20170174668
    Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula (I), wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    Type: Application
    Filed: November 28, 2014
    Publication date: June 22, 2017
    Inventors: Joerg Kley, Andreas Blum, Dirk Gottschling, Joerg P. Hehn, Dieter Wiedenmayer
  • Patent number: 9139577
    Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined in the description and claims, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: September 22, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Blum, Dirk Gottschling, Armin Heckel, Joerg P. Hehn, Bernhard Schmid, Dieter Wiedenmayer
  • Patent number: 9029360
    Abstract: This invention relates to novel pyrazolopyrimidines and their use as metabotropic glutamate 5 receptor antagonists (mGlu5 receptor antagonists), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of mGlu5 receptor mediated disorders.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: May 12, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Heiner Ebel, Doris Riether, Bernd Wellenzohn
  • Patent number: 8952014
    Abstract: The present invention relates to the new compounds of general formula I wherein A, U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers thereof, the diastereomers, the enantiomers, the hydrates, the mixtures and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: February 10, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
  • Patent number: 8901138
    Abstract: This invention relates to novel sulfoximine substituted quinazoline derivatives of formula I wherein Ar, R1 and R2 are as defined herein, and their use as MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) kinase inhibitors, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment or amelioration of MNK1 (MNK1a or MNK1b) and/or MNK2 (MNK2a or MNK2b) mediated disorders.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: December 2, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Andreas Blum, Dirk Gottschling, Armin Heckel, Joerg Hehn, Thorsten Lehmann-Lintz, Dieter Wiedenmayer
  • Patent number: 8829006
    Abstract: The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2, R3 and R4 are defined as mentioned in the description, the tautomers thereof, the isomers thereof, the diastereomers thereof, the enantiomers thereof, the hydrates thereof, the mixtures thereof and the salts thereof as well as the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Georg Dahmann, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
  • Patent number: 8765763
    Abstract: The present invention relates to new CGRP-antagonists of general formula I wherein R1, R2, R3, Ra, Rb, Rc, X, Y and Z are defined as mentioned hereinafter, the individual diastereomers, the individual enantiomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, medicaments containing these compounds, the use thereof and processes for the preparation thereof.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: July 1, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alexander Dreyer, Henri Doods, Kai Gerlach, Dirk Gottschling, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle
  • Patent number: 8629137
    Abstract: The present invention relates to new CGRP-antagonists of general formula I wherein U, V, X, Y, R1, R2 and R3 are defined as stated hereinafter, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, the mixtures thereof and the salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: January 14, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Georg Dahmann, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
  • Patent number: 8450327
    Abstract: The present invention relates to novel CGRP antagonists of the general formula (I) in which U, V, X, Y, R1, R2, R3 are defined as described below, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures and salts thereof, and the hydrates of the salts, particularly the physiologically compatible salts thereof having inorganic or organic acids or bases, pharmaceuticals comprising said compounds, the use thereof, and the method for the production thereof.
    Type: Grant
    Filed: October 16, 2008
    Date of Patent: May 28, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dirk Gottschling, Georg Dahmann, Henri Doods, Annekatrin Heimann, Stephan Georg Mueller, Klaus Rudolf, Gerhard Schaenzle, Dirk Stenkamp
  • Patent number: RE49699
    Abstract: The invention related to compounds of formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R2, A, Y and L are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: October 17, 2023
    Assignees: Boehringer Ingelheim International GmbH, Hydra Biosciences, LLC
    Inventors: Thierry Bouyssou, Dirk Gottschling, Niklas Heine, Lana Louise Smith Keenan, Michael D. Lowe, Hossein Razavi, Christopher Ronald Sarko, Simon Surprenant, Hidenori Takahashi, Michael Robert Turner, Xinyuan Wu